Damian Lismore has commercial, international and listed company experience (both ASX and NASDAQ) covering many industries including healthcare and technology.
In his executive career, Mr Lismore held CEO, CFO and company secretarial roles; and continues to act as an advisor to CEOs, boards and business owners. He has a background in M&A, licensing and business financing.
Mr Lismore is the chief financial officer of Scout Bio, a Frazier Healthcare-backed company commercialising gene therapy products. He was also chief financial officer of Nexvet Biophama which attracted significant US institutional backing and listed on NASDAQ in 2015. The business evolved to have research capabilities in Australia, clinical operations in the US and manufacturing operations in Ireland. In 2017, following the successful completion of clinical trials for its lead program the business was acquired by Zoetis. He was also chief financial officer of Biota where he was instrumental in securing and managing major licences with global pharmaceutical companies and securing a major US grant that allowed the business to transition from the ASX to NASDAQ.